Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Göttmann, Uwe [VerfasserIn]   i
 Woude, Fokko J. van der [VerfasserIn]   i
 Braun, Claude [VerfasserIn]   i
Titel:Endothelin receptor antagonists
Titelzusatz:a new therapeutic option for improving the outcome after solid organ transplantation?
Verf.angabe:Uwe Göttmann, Fokko J. van der Woude, Claude Braun
Jahr:2003
Umfang:19 S.
Fussnoten:Gesehen am 01.06.2022
Titel Quelle:Enthalten in: Current vascular pharmacology
Ort Quelle:Hilversum [u.a.] : Bentham Science Publ., 2003
Jahr Quelle:2003
Band/Heft Quelle:1(2003), 3, Seite 281-299
ISSN Quelle:1875-6212
Abstract:Initially described as the most potent vasoconstrictor peptide, endothelin (ET) has also been shown to possess extraordinary immunomodulatory and proinflammatory properties. Because of this broad spectrum of biological activities, a possible role of the ET-system in solid organ transplantation has soon become a focus of research. Several studies demonstrated a pathogenetic involvement of ET in ischemia/reperfusion injury of heart, liver, kidney, and lung grafts. ET accumulates during cold storage of organs and can be detected in the effluent preservation solution. In addition ET is very, likely to play a pivotal role in the development of chronic rejection, which represents the major cause of late allograft loss. Increased expression of components of the ET-system has been described in areas of neointimal proliferation, a hallmark of chronic graft rejection. Both selective ET-A as well as non-selective ET-A/B receptor antagonists improved histomorphological and functional sequelae of chronic rejection. However these data have largely been derived from experimental animal transplantation, and ET receptor blockers have only recently been introduced in clinical medicine. A significant number of investigational drugs are now being tested in humans, with a main focus on cardiovascular diseases, such as congestive heart failure and pulmonary hypertension. First results have markedly dampened the initial enthusiastic vision of ET receptor blockers being organoprotective super-weapons. Thus the clinical potential of ET antagonists in general, and especially in solid-organ transplantation, is still to be defined.
DOI:doi:10.2174/1570161033476655
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.2174/1570161033476655
 Volltext: https://www.eurekaselect.com/article/26048
 DOI: https://doi.org/10.2174/1570161033476655
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Animals
 Endothelin Receptor Antagonists
 Endothelin-1
 Endothelins
 Graft Rejection
 Humans
 Organ Transplantation
 Randomized Controlled Trials as Topic
 Receptors, Endothelin
 Treatment Outcome
K10plus-PPN:1805503278
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68924861   QR-Code
zum Seitenanfang